{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Barclay ME"],"funding":["Department of Health, Government of Western Australia","Cancer Council Victoria","Cancer Research UK","Kreftforeningen","Public Health Wales","AHRQ HHS","Kræftens Bekæmpelse","DG Health and Social Care of the Scottish Government","Cancer Society of New Zealand","Partenariat Canadien Contre Le Cancer","National Cancer Registry Ireland","Public Health Agency Northern Ireland","Cancer Institute NSW","National Health Service England"],"pagination":["e000800"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12258358"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(1)"],"pubmed_abstract":["<h4>Abstract</h4><h4>Background</h4>International variation in lung cancer survival may be partly explained by variation in stage-specific treatment use, but relevant comparative evidence is sparse. As part of the International Cancer Benchmarking Partnership, we examined use of chemotherapy and radiotherapy in population-based cancer registry data.<h4>Methods</h4>Linked population-based data sources were used to describe use and time to first treatment for either chemotherapy or radiotherapy in patients with lung cancer diagnosed in study periods during 2012-2017 in 16 jurisdictions of Australia, Canada, the UK and Norway.<h4>Results</h4>There was large variation in the proportions of patients with lung cancer receiving chemotherapy (ranging from 23% in Northern Ireland to 45% in Norway) "],"journal":["BMJ oncology"],"pubmed_title":["Chemotherapy and radiotherapy use in patients with lung cancer in Australia, Canada, the UK and Norway 2012-2017: an ICBP population-based study."],"pmcid":["PMC12258358"],"funding_grant_id":["R01 HS024284","C18081/A18180","International Cancer Benchmarking Partnership","EDDAPA-2022/100002"],"pubmed_authors":["Saint-Jacques N","Shack L","Finley CJ","Lawler M","Habbous S","Ransom DT","Dewar RA","Wang H","Fung S","Swann R","Dawkins PA","Navas EG","Butler J","Denny CA","Zhang B","Sarker S","Morrison DS","Green KE","Woods RR","Nilssen Y","Moller B","Bucher O","Thomson CS","McClure CA","ICBP Module 9 Lung Study Group","Baldwin D","Barisic A","Creighton N","Wong THT","Donnelly DW","Finn N","Harrison S","May L","Johnson SA","Barclay ME","Kumar SE","Huws DW","Alvi R","Dowden JJ","Walton R","Cameron DA","Bennett DB","Te Marvelde L","McPhail S","Tian X","Downie L","Thomas RJ","Han J","Musto G","You H","Lyratzopoulos G"],"additional_accession":[]},"is_claimable":false,"name":"Chemotherapy and radiotherapy use in patients with lung cancer in Australia, Canada, the UK and Norway 2012-2017: an ICBP population-based study.","description":"<h4>Abstract</h4><h4>Background</h4>International variation in lung cancer survival may be partly explained by variation in stage-specific treatment use, but relevant comparative evidence is sparse. As part of the International Cancer Benchmarking Partnership, we examined use of chemotherapy and radiotherapy in population-based cancer registry data.<h4>Methods</h4>Linked population-based data sources were used to describe use and time to first treatment for either chemotherapy or radiotherapy in patients with lung cancer diagnosed in study periods during 2012-2017 in 16 jurisdictions of Australia, Canada, the UK and Norway.<h4>Results</h4>There was large variation in the proportions of patients with lung cancer receiving chemotherapy (ranging from 23% in Northern Ireland to 45% in Norway) ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-02T00:16:26.472Z","creation":"2026-05-24T03:07:37.289Z"},"accession":"S-EPMC12258358","cross_references":{"pubmed":["40662158"],"doi":["10.1136/bmjonc-2025-000800"]}}